GB2375172A - Fas pathway genes - Google Patents

Fas pathway genes Download PDF

Info

Publication number
GB2375172A
GB2375172A GB0219775A GB0219775A GB2375172A GB 2375172 A GB2375172 A GB 2375172A GB 0219775 A GB0219775 A GB 0219775A GB 0219775 A GB0219775 A GB 0219775A GB 2375172 A GB2375172 A GB 2375172A
Authority
GB
United Kingdom
Prior art keywords
compound
gene
cell
stimulates
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0219775A
Other versions
GB0219775D0 (en
Inventor
Louis Paul Deiss
Fruma Yehiely
Paz Einat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quark Pharmaceuticals Inc
Original Assignee
Quark Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Biotech Inc filed Critical Quark Biotech Inc
Publication of GB0219775D0 publication Critical patent/GB0219775D0/en
Publication of GB2375172A publication Critical patent/GB2375172A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

There is provided a method for identifying a compound which stimulates or inhibits cell apoptosis by contacting a cell expressing a gene with the compound and determining the ability of the compound to stimulate or inhibit apoptosis of the cell as compared to a control. Also provided is a method of treating degenerative disease, auto-immune disease, and tumors in a subject by administering to the subject a therapeutically effective amount of a compound which stimulates a gene in the Fas pathway. The use of a casein kinase inhibitor, dicumarol, sulfinpyrazone, Nrf-2 inhibitor, or a glutathione precursor in the preparation of a medicament is also provided. Also provided is a method of preparing a pharmaceutical composition which includes determining whether a compound stimulates or inhibits a Fas-pathway gene using the above method, and admixing the compound with a pharmaceutically acceptable carrier. A method for the identification of genes that encode for inhibitors of cell death by inactivating genes in cells by sensitizing cells to cell death, using gene inactivators, applying positive selection to the sensitized cells and utilizing subtraction analysis to identify the genes that have been inactivated is also provided.

Description

{57) There is provided a method for identifying a compound which
stimulates or inhibits cell apoptosis by contacting a cell expressing a gene with the compound and determining the ability of the compound to stimulate or inhibit apoptosis of the cell as compared to a control. Also provided is a method of treating degenerative disease, auto-immune disease, and tumors in a subject by administering to the subject a therapeutically effective amount of a compound which stimulates a gene in the Fas pathway. The use of a casein kinase inhibitor, dicumarol, sulfinpyrazone, Nrf-2 inhibitor, or a glutathione precursor in the preparation of a medicament is also provided. Also provided is a method of preparing a pharmaceutical composition which includes determining whether a compound stimulates or inhibits a Fas-pathway gene using the above method, and admixing the compound with a pharmaceutically acceptable carrier. A method for the identification of genes that encode for inhibitors of cell death by inactivating genes in cells by sensitizing cells to cell death, using gene inactivators, applying positive selection to the sensitized cells and utilizing subtraction analysis to identify the genes that have been inactivated is also provided.
GB0219775A 2000-02-07 2001-02-07 Fas pathway genes Withdrawn GB2375172A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49955300A 2000-02-07 2000-02-07
PCT/US2001/003946 WO2001057189A2 (en) 2000-02-07 2001-02-07 Fas pathway genes

Publications (2)

Publication Number Publication Date
GB0219775D0 GB0219775D0 (en) 2002-10-02
GB2375172A true GB2375172A (en) 2002-11-06

Family

ID=23985704

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0219775A Withdrawn GB2375172A (en) 2000-02-07 2001-02-07 Fas pathway genes

Country Status (4)

Country Link
AU (1) AU2001236733A1 (en)
GB (1) GB2375172A (en)
IL (1) IL151079A0 (en)
WO (1) WO2001057189A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027321A2 (en) * 2001-09-24 2003-04-03 University Of Aarhus Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
DE10147088A1 (en) * 2001-09-25 2003-04-17 Medinnova Ges Med Innovationen Use of active substances for the prophylaxis and / or therapy of diseases which are associated with cell growth disorders and test system for finding such active substances
FR2853911B1 (en) * 2003-04-17 2005-07-08 Merck Sante Sas INSULIN-INDUCED GENE AS A THERAPEUTIC TARGET IN DIABETES
WO2005046726A2 (en) * 2003-11-12 2005-05-26 Allergan, Inc. Combinations for inhibiting cell growth which contains an inhibitor of human ck1 alpha activity and a rxr agonist
AU2006249780A1 (en) * 2005-05-26 2006-11-30 The Johns Hopkins University Compositions and methods for the treatment or prevention of chemoresistant neoplasia
CN111068053A (en) * 2014-02-03 2020-04-28 耶路撒冷希伯来大学的益生研究开发有限公司 Use of casein kinase I inhibitors to deplete stem cells
KR20200140805A (en) 2018-02-21 2020-12-16 브리스톨-마이어스 스큅 컴퍼니 CAMK2D antisense oligonucleotide and uses thereof
CN111671749A (en) * 2020-06-12 2020-09-18 重庆医科大学 Application of dicoumarol in preparation of HBx protein stability inhibitor
CN112121043A (en) * 2020-10-27 2020-12-25 澳门大学 Application of dicoumarol in antitumor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612180A (en) * 1993-05-13 1997-03-18 Board Of Trustees Of The Leland Stanford Junior University Genetic footprinting: insertional mutagenesis and genetic selection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612180A (en) * 1993-05-13 1997-03-18 Board Of Trustees Of The Leland Stanford Junior University Genetic footprinting: insertional mutagenesis and genetic selection

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Blood, Vol.92, 1998, Lecine, P. et al., "Mice lacking transcription factor NF-E2 provide in vivo...", pp.1608-1616. *
J. Biol. Chem., Vol. 273, 1998, Wang, Y. et al., "The identification of a C-element and a trans-acting factor...", pp.34623-34630 *
J. Biol. Chem., Vol.270, 1995, Beyaert, R. et al., "Casein kinase-1 phosphorylates the p75 tumour necrosis factor...", pp.23293-23299 *
J. Biol. Chem., Vol.273, 1998, Morrow, C. S. et al., "Coordinated action of glutathione S-transferases...", pp.20114-20120. *
Science, Vol., 274, 1996, Smith, V. et al., "Functional analysis of the genes of Yeast chromosome V...", pp.2069-2074. *

Also Published As

Publication number Publication date
GB0219775D0 (en) 2002-10-02
WO2001057189A9 (en) 2002-10-24
WO2001057189A2 (en) 2001-08-09
AU2001236733A1 (en) 2001-08-14
WO2001057189A3 (en) 2002-05-02
IL151079A0 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
Liu et al. PROTACs: A novel strategy for cancer therapy
Zhang et al. A NIK-IKKα module expands ErbB2-induced tumor-initiating cells by stimulating nuclear export of p27/Kip1
Tomasi et al. S‐adenosyl methionine regulates ubiquitin‐conjugating enzyme 9 protein expression and sumoylation in murine liver and human cancers
Burhans et al. The cell cycle is a redox cycle: linking phase-specific targets to cell fate
Ackerman et al. Regulation of casein kinase II activity by epidermal growth factor in human A-431 carcinoma cells
Murugan et al. Ras oncogenes in oral cancer: the past 20 years
Wu et al. Crosstalk of intracellular post-translational modifications in cancer
Menendez et al. Gerosuppressant metformin: less is more
Park et al. Effect of tetrandrine on experimental hepatic fibrosis induced by bile duct ligation and scission in rats
Sun et al. An overview: the diversified role of mitochondria in cancer metabolism
Papeleu et al. Trichostatin A induces differential cell cycle arrests but does not induce apoptosis in primary cultures of mitogen-stimulated rat hepatocytes
Sessions et al. Mitochondrial dynamics in cancer stem cells
NO20050793L (en) Use of urease for inhibition of cancer cell growth
Gum et al. Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and-independent signaling modules
GB2375172A (en) Fas pathway genes
Guerra et al. Protein kinase CK2 inhibition is associated with the destabilization of HIF-1α in human cancer cells
Baines et al. Selenomethionine inhibits growth and suppresses cyclooxygenase-2 (COX-2) protein expression in human colon cancer cell lines
Rishikof et al. Phenylbutyrate decreases type I collagen production in human lung fibroblasts
Wang et al. RHO GTPase family in hepatocellular carcinoma
Ranek et al. Muscarinic 2 receptors modulate cardiac proteasome function in a protein kinase G-dependent manner
Niki et al. DJ-1-binding compound B enhances Nrf2 activity through the PI3-kinase-Akt pathway by DJ-1-dependent inactivation of PTEN
Markovits et al. Differential effects of two growth inhibitory K vitamin analogs on cell cycle regulating proteins in human hepatoma cells
Haddad et al. Inhibition of glutathione-related enzymes augments LPS-mediated cytokine biosynthesis: involvement of an IκB/NF-κB-sensitive pathway in the alveolar epithelium
Kim et al. Ubiquitin-proteasome pathway as a primary defender against TRAIL-mediated cell death
Dai et al. A novel synthetic small molecule YH‐306 suppresses colorectal tumour growth and metastasis via FAK pathway

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)